Treatment outcome and prognostic factors in childhood acute myeloblastic leukemia: A report from the Japanese Children's Cancer and Leukemia Study Group (CCLSG)

International Journal of Hematology

Volumn 66, Issue 1, 1997, Pages 103-110

  Katano, Naoyuki ^a   Tsurusawa, Masahito ^a   Hirota, Takahisa ^a   Horikoshi, Yasuo ^b   Mimaya, Junichi ^b   Yanai, Masanori ^c   Tsuji, Yoshio ^c   Fujimoto, Takeo ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myeloblastic leukemia; Childhood; Prognosis; Risk factors; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ENOCITABINE; MERCAPTOPURINE; PREDNISOLONE; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; HUMAN; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 0031193395     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(97)00582-3     Document Type: Article

References (18)

1. Hurwitz CA, Mounce KG, Grier HE. Treatment of patients with acutue myelogenous leukemia: review of clinical trials of the past decade. J Pediatr Hematr Oncol 1995;17:185-197.
2. Dahl GV, Kalwinsky DK, Mirro J, Look AT, Pui CH, Murphy SB, Mason C, Ruggiero M, Schell M, Johnson FL, Thomas ED. Allogenic bone marrow transplantation in a program of intensive sequentatial chemotherapy for children and young adults with acute nonlymphoblastic leukemia in first remission. J Clin Oncol 1990;8:295-303.
3. Bleyer WA, Sather H, Coccia P. The staging of childhood acute lymphoblastic leukemia: strategies of the children's cancer study group and a three-dimensional technique of multivariate analysis. Med Pediatr Oncol 1986;68:205-212.
4. Grier HE, Gelber RD, Camitta BM, Delorey MJ, Link MP, Price KN, Leavitt PR, Weinstein HJ. Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol 1987;5:1026-1032.
5. Bukley JD, Chard RL, Bahener RL, Nesbit ME, Lampkin BC, Woods WG, Hammond GD. Important in outcome for children with acute nonlymphoblastic leukemia: a report from the childrens Cancer study group. Cancer 1989;63:1457-1465.
6. Creutzig U, Ritter J, and Gunther Schellong for the AML-BFM Study Group. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study ANL-BFM-78. Blood 1990;75:1932-1940.
7. Hurwitz CA, Schell MJ, Pui CH, Crist WM, Behm F, Mirro, Jr. J. Adverse prognostic features in 251 children treated for acute myeloid leukemia. Med Clin Oncol 1993;21:1-7.
8. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick H, Sultan C. Proporsals for the classification of the acute leukemias. Br J Haematol 1976;33:451-458.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;52:203-224.
10. Ritter J, Cretzig U, Schellong G for the AML-BFM-Group. Treatment results of the three consecutive German childhood AML trials; BFM-78, -83, and -87. Leukemia 1992;6 Suppl 2;59-62.
11. Grier HE, Gelber RD, Link MP, Camitta BP, Clavell LA, Weistein HJ. Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze. Leukemia 1992;6 Suppl 2;48-51.
12. Pui CH, Cahl G. Central nervous system leukemia in children with acute nonlymphoblastic leukemia. Blood 1985;66:1062-1067.
13. Odom LF, Gordon EM. Acute monoblastic leukemia in infancy and early childhood: Successful treatment with epipodophyllotoxin. Blood 1984;64:875-882.
14. M-Climent JA, Lane NJ, Rubin CM, Morgen E, Johnstone HS, Mick R, Murphy SB, Vardiman JW, Larson RA, Le Beau MM, Rowley JD. Clinical and prognostic significance of chromosomal abnomalities in childhood acute myeloid leukemia de novo. Leukemia 1995;9:95-101.
15. Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 1994;8:1269-1274.
16. Preisler HD, Azarnia N, Marinello. Relationship of the growth of leukemic cells in vitro to outcome of therapy for acute nonlymphoblastic leukemia. Cancer Res 1984;44:1712-1717.
17. McCulloch EA, Curtis JE, Messner HA, Senn JS, Germanson TP. The contribution of blast cell properties to outcome variation in acute myeloblastic leukemia(AML). Blood 1982;59:601-608.
18. Meng-er H, Yu-chen Y, Shu-rong C, Jin-ren C, Jia-Xiang L, Lin Z, Long-jun Gu, Zhen-yi W. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-572.